Pending acquisition: Viatris is acquiring Pacira for $36.50 per share in cash. Tender offer expires November 16, 2026.
What they do
Our principal executive offices and corporate headquarters are located in Brisbane, California. Trademarks and Service Marks Pacira ® , EXPAREL ® , ZILRETTA ® , iovera ® °, the Pacira logo and other trademarks or service marks of Pacira appearing in this Annual Report are the property of Pacira, and when first used in each part of this Annual Report, include the ® symbol.
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Share structure
Common
39.9M
Pre-funded warrants
0.0M
Options
6.1M
RSUs
—
Warrants
—
Converts
7.1M
Conv preferred
0.0M
ESPP reserve
—
FDSO
53.1M
Cap table as of 2026-08-03.
Viatris announced on October 8, 2026 that it will acquire Pacira for $36.50 per share in cash. Viatris launched a tender offer on October 30, 2026 that expires at the end of the day on November 16, 2026 unless extended; a merger follows the tender under the merger agreement, whose outside date is April 8, 2027. Pacira's board recommended the offer in its October 30, 2026 Schedule 14D-9. The share counts and cash on this page are Pacira standalone and stay accurate until the deal closes; after closing the stock will be delisted.
Price history
Loading PCRX daily closes…
Loading price history…
Next catalyst
ZILRETTA · Est. Nov 7, 2026 · guidance midpoint · guided Now
Upcoming catalysts
Expected
Drug
Phase
Indication
Mgmt guide
GUIDEDEst. Nov 7, 2026Now
guidance midpoint
ZILRETTA
Phase 3 registration study in shoulder osteoarthritis topline
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Approved · ActiveModality: Liposomal injectable suspension (pMVL drug delivery technology)
Partnerships LG Chem (Jan 2026): exclusive rights to commercialize EXPAREL in select Asia-Pacific markets; Pacira manufactures. Marketing authorization filed in South Korea and Thailand.
Indications
Postsurgical local analgesia via infiltration (patients 6+ years)(Approved)
Status note Commercialized in the US since Apr 2012; approved in select European countries and the UK (Nov 2021). Pediatric study commitments ongoing; FDA/EMA waived pediatric requirements for nerve-block indications.
Partnerships J&J MedTech (Jul 2025): exclusive third-party co-promoter for ZILRETTA in the US (initial term through 2031); Johnson & Johnson MedTech sales force extends reach beyond orthopedics. Acquired via Flexion Therapeutics (Nov 2021; contingent milestones through Dec 2030)
Indications
Osteoarthritis knee pain(Approved)
Status note First and only extended-release intra-articular injection indicated for OA knee pain.
Partnerships Baylor College of Medicine: exclusive worldwide license to underlying PCRX-201 patents. Acquired via Flexion (Nov 2021); company holds a stake in GQ Bio (HCAd platform).
Indications
Osteoarthritis knee pain(Phase 2)
Status note Locally administered gene therapy for OA knee pain. FDA RMAT designation Feb 2024. Lead program from proprietary high-capacity adenovirus (HCAd) vector platform.
PCRX-2002
Phase 2 · ActiveModality: Long-acting formulation
Indications
Postsurgical pain(Phase 2)
Status note Complementary long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.